3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Glioblastoma
6
Neuroblastoma
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Medulloblastoma
3
Glioma
3
Brain Neoplasms
3
Sarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Ependymoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pyloric Stenosis, Hypertrophic
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Carcinoma
1
Brainstem Glioma
1
Astrocytoma
1
Interventions
Temozolomide
8
Irinotecan
7
Melphalan
6
Cyclophosphamide
6
X-Rays
5
Topotecan
5
Phantoms, Imaging
5
Magnetic Resonance Spectroscopy
5
Granulocyte Colony-Stimulating Factor
5
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Busulfan
4
palbociclib
3
fludarabine
3
Vincristine
3
Thiotepa
3
Stem Cell Transplantation
3
Sirolimus
3
Nivolumab
3
Etoposide
3
Bone Marrow Transplantation
3
Biopsy
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
omburtamab I-131
2
olaparib
2
larotrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
Celecoxib
×
CNS
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled